Anand Shah, M.D. is a nationally recognized physician leader and health policy expert who most recently served as the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration. Dr. Shah led the agency’s operations as it relates to medical and scientific affairs. He was responsible for developing and leading high-priority policy in support of FDA’s public health mission. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Governors, and local governments. He regularly briefed bipartisan bicameral Congressional leadership on the formulation of public health policies and programs.
Dr. Shah’s efforts have focused on bringing new technologies to market, redesigning health care delivery and payment, and expanding competition and consumer choice. At FDA, he developed consensus policy on fit-for-purpose programs including Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, COVID-19 vaccine development, digital health, consumer protection, and clinical trials. He developed a science and technology incubator designed to harness the power of real-world evidence and artificial intelligence to improve health outcomes.
He previously served in two senior leadership roles at the Centers for Medicare & Medicaid Services where he led the development of numerous market-driven, innovative policies and programs. As Senior Medical Advisor, he was the primary counselor for agency-wide policy related to medical and scientific innovation. Dr. Shah established consensus on several critical policy initiatives including aligning payment and prevention to increase Medicare beneficiaries’ access to novel antimicrobials, expanding patients’ access to new cell and gene therapies, and streamlining Medicare access to breakthrough technologies. As the Chief Medical Officer of the Center for Medicare & Medicaid Innovation, Dr. Shah led the clinical design of novel value-based payment and service delivery models including those for advanced primary care, specialty care, and prescription drugs.